1 / 1

What reasons do patients give for declining or participating in early phase cancer trials?

What reasons do patients give for declining or participating in early phase cancer trials? Susan Catt 1 , Carolyn Langridge 1 , Valerie Jenkins 1 , Denis Talbot 2 , Lesley Fallowfield 1 1 CRUK Psychosocial Oncology Group, Brighton & Sussex Medical School

chars
Télécharger la présentation

What reasons do patients give for declining or participating in early phase cancer trials?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What reasons do patients give for declining or participating in early phase cancer trials? Susan Catt1, Carolyn Langridge1,Valerie Jenkins1, Denis Talbot2, Lesley Fallowfield1 1 CRUK Psychosocial Oncology Group, Brighton & Sussex Medical School 2 University of Oxford Medical Oncology Unit Background Communication with patients contemplating early phase cancer trial participation can be challenging. It is an ethical imperative that consent is given freely and that it is both informed and educated. Controversy exists as to whether or not patients are provided with information that is comprehensive enough to permit truly informed consent1. Even if communication is appropriate, appreciation of other factors motivating trial entry is important. We present data from a larger CRUK funded communication study2 examining the reasons patients gave for accepting or declining Phase I/II trials. ID 16 “Now back with my husband, moving back to Wales to make the most of whatever time I have left.” ID 20 “Quality of life is far more important than quantity.” frequency ConclusionsPatients considering PI/II trials may be a self-selected group with optimistic expectations for personal benefit helping to drive trial entry. Achieving genuinely informed consent and avoidance of therapeutic misconceptions in such patients might be difficult. A communication skills course informed by these data has been developed (see poster A59) . References: 1Jenkins, V, Anderson, J, Fallowfield, L. 2010 Support Care Cancer, 18 (9):1115-21. 2Jenkins, Solis-Trapala, Langridge, Catt, Talbot, Fallowfield. 2010 Journal of Clinical Oncology (in press) Acknowledgements: Cancer Research UK funded this work. We thank all patients who participated.

More Related